INSM

Insmed Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth 1/10
  • Momentum 8/10
Insmed sales and earnings growth
INSM Growth
Low
  • Revenue Y/Y 66.73%
  • EPS Y/Y -15.26%
  • FCF Y/Y -37.09%
Insmed gross and profit margin trends
INSM Profitability
Neutral
  • Gross margin 79.70%
  • EPS margin -210.50%
  • ROIC -62.30%
Insmed net debt vs free cash flow
INSM Risk
Good
  • Debt / Equity 1.0
  • Debt / FCF 0.2
  • Interest coverage -14.2

Insmed stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.

More Biotechnology stocks ↗